How does the change affect a highly deductible health plan for children with asthma? A new study led by researchers at the Harvard Pilgrim Health Care Institute suggests that enrollment in a highly deductible health plan (HDHP) may not be associated with changes in asthma medication use or asthma exacerbations. when drugs are exempt from the deductible. The findings were published in JAMA Pediatrics on May 10th.
Treat asthma, clinical guidelines recommend the use of control drugs, but adherence to these drugs is generally poor, putting those affected by asthma exacerbations at risk. High out-of-pocket costs have been associated with decreased driver medication use and adverse asthma results for children and adults. Although most of the evidence for HDHPs comes from studies focused on adult populations, the study team, led by Alison Galbraith, MD, MPH, lead author and associate professor in the Department of Population Medicine Harvard Medical School, examined how enrollment in HDHPs may affect. use of asthma control drugs and exacerbation in children.
“A challenge in insurance design is to balance affordable coverage with access to the care needed for chronic conditions for both children and adults,” Dr. Galbraith said. “Our findings highlight the potential protective effect of the franchise’s asthma medication exemption on high-deductible health plans.”
The study population, extracted from a large, national commercial database, included children (4–17 years) and adults (18–64 years) with persistent asthma who switched from traditional plans to HDHP during a period of 24 months. Compared to those maintained in traditional plans, children switching to HDHPs experienced small decreases in 30-day annual fillings for long-acting beta-agonist beta-corticosteroid inhaled drugs, but not for other drugs. drivers. Adults switching to HDHPs had no significant reductions in 30-day fillings for any control drug. There were no statistically significant differences in medication adherence, oral steroid bursts, or asthma-related ED visits for children or adults.
As for the possible next steps, Dr. Galbraith adds: “Asthma is one of the leading causes of preventable disease burden for both children and adults. Policy makers should consider adopting value-based designs and other policies that exempt important drugs for to asthma and others chronic conditions—Which could prevent adverse clinical outcomes— from the deductible “.
Alison A. Galbraith et al, Controller of medication use and exacerbations for children and adults with asthma in highly deductible health plans, JAMA Pediatrics (2021). DOI: 10.1001 / jamapediatrics.2021.0747
Provided by Harvard Pilgrim Health Care Institute
Citation: Medication Use for Asthma and Exacerbations (2021, May 25) Retrieved May 25, 2021 at https://medicalxpress.com/news/2021-05-asthma-medication-exacerbations.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.